v3.26.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
REVENUE    
Sales $ 12,159 $ 1,018
Cost of goods sold 9,291 734
Gross profit 2,868 284
OPERATING EXPENSES    
General and administrative expenses $0 and $0 in stock-based compensation, respectively 3,317,648 4,348,274
Research and development $0 and $10,000 in stock-based compensation, respectively 1,047,083 1,209,205
Sales and marketing $0 and $0 in stock-based compensation, respectively 50,920
Total operating expenses 4,364,731 5,608,399
NET LOSS FROM OPERATIONS (4,361,863) (5,608,115)
OTHER INCOME (EXPENSE)    
Interest expense (27,136) (157,499)
Interest income 280 288
Amortization of debt discount (24,687) (200,284)
Change in fair value of derivative liabilities (11,800,798) 13,145
Change in fair value of Evofem warrants 25,004
Total other expense (11,827,337) (344,350)
Net loss before income taxes (16,189,200) (5,952,465)
Income tax provision
NET LOSS (16,189,200) (5,952,465)
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (241,475) (242,156)
NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES $ (15,947,725) $ (5,710,309)
Net loss per share, basic (in Dollars per share) $ (790.49) $ (198,072.98)
Net loss per share, diluted (in Dollars per share) $ (790.49) $ (198,072.98)
Weighted average number of shares outstanding during the period, basic (in Shares) 20,174 29
Weighted average number of shares outstanding during the period, diluted (in Shares) 20,174 29
COMPREHENSIVE LOSS:    
Net Loss $ (16,189,200) $ (5,952,465)
Other Comprehensive Income:    
Change in fair value of Evofem note receivable 107,805
TOTAL COMPREHENSIVE LOSS $ (16,081,395) $ (5,952,465)